Kenvue Inc. (NYSE:KVUE) Shares Purchased by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC lifted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 250.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 58,135 shares of the company's stock after buying an additional 41,527 shares during the quarter. Concurrent Investment Advisors LLC's holdings in Kenvue were worth $1,394,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of KVUE. Price T Rowe Associates Inc. MD increased its holdings in Kenvue by 3.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares during the period. Vanguard Group Inc. increased its holdings in Kenvue by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after purchasing an additional 1,636,741 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Geode Capital Management LLC increased its holdings in Kenvue by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after purchasing an additional 1,391,854 shares during the period. Finally, Franklin Resources Inc. increased its holdings in Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after purchasing an additional 16,269,721 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Redburn Atlantic initiated coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective on the stock. UBS Group raised their price objective on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Friday, May 9th. Barclays lifted their price target on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. Citigroup reiterated a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. Finally, Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $25.33.

Kenvue Price Performance

KVUE stock traded down $0.19 during trading on Tuesday, hitting $20.71. The stock had a trading volume of 16,971,258 shares, compared to its average volume of 16,126,705. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.86 and a quick ratio of 0.60. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $25.17. The stock has a market capitalization of $39.74 billion, a P/E ratio of 37.66, a PEG ratio of 3.27 and a beta of 0.83. The company's 50-day moving average price is $22.57 and its two-hundred day moving average price is $22.32.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The company had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. During the same period in the previous year, the firm posted $0.28 EPS. Kenvue's revenue was down 3.9% compared to the same quarter last year. As a group, research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.96%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.